These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30596408)

  • 41. Prognostic Value of Brain Metastasis-Free Interval in Patients with Breast Cancer Brain Metastases.
    Hulsbergen AFC; Lamba N; Claes A; Kavouridis VK; Lin NU; Smith TR; Verhoeff JJC; Broekman MLD
    World Neurosurg; 2019 Aug; 128():e157-e164. PubMed ID: 31035019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
    Lindman H; Wiklund F; Andersen KK
    BMC Cancer; 2022 Sep; 22(1):1006. PubMed ID: 36138404
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.
    Kim YJ; Kim JS; Kim IA
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1803-1816. PubMed ID: 29971531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Triple-negative breast cancer with brain metastases: a comparison between basal-like and non-basal-like biological subtypes.
    Niwińska A; Olszewski W; Murawska M; Pogoda K
    J Neurooncol; 2011 Dec; 105(3):547-53. PubMed ID: 21656328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The relevance of intrinsic subtype to clinicopathological features and prognosis in 4,266 Japanese women with breast cancer.
    Shibuta K; Ueo H; Furusawa H; Komaki K; Rai Y; Sagara Y; Kamada Y; Tamaki N
    Breast Cancer; 2011 Oct; 18(4):292-8. PubMed ID: 20571962
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
    Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brain metastases free survival differs between breast cancer subtypes.
    Berghoff A; Bago-Horvath Z; De Vries C; Dubsky P; Pluschnig U; Rudas M; Rottenfusser A; Knauer M; Eiter H; Fitzal F; Dieckmann K; Mader RM; Gnant M; Zielinski CC; Steger GG; Preusser M; Bartsch R
    Br J Cancer; 2012 Jan; 106(3):440-6. PubMed ID: 22233926
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.
    Shen Q; Sahin AA; Hess KR; Suki D; Aldape KD; Sawaya R; Ibrahim NK
    Oncologist; 2015 May; 20(5):466-73. PubMed ID: 25802405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biological subtypes and survival outcomes in breast cancer patients with brain metastases (study of the Anatolian Society of Medical Oncology).
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Unal OU; Mert AG; Bilici M; Ozkan M; Elkiran ET; Yaman S; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Urakci Z; Buyukberber S
    Oncology; 2012; 83(3):141-50. PubMed ID: 22814315
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
    Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
    Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Distant metastasis in triple-negative breast cancer.
    Tseng LM; Hsu NC; Chen SC; Lu YS; Lin CH; Chang DY; Li H; Lin YC; Chang HK; Chao TC; Ouyang F; Hou MF
    Neoplasma; 2013; 60(3):290-4. PubMed ID: 23373998
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ER
    Arciero CA; Guo Y; Jiang R; Behera M; O'Regan R; Peng L; Li X
    Clin Breast Cancer; 2019 Aug; 19(4):236-245. PubMed ID: 30846407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognosis of Japanese breast cancer based on hormone receptor and HER2 expression determined by immunohistochemical staining.
    Nakajima H; Fujiwara I; Mizuta N; Sakaguchi K; Hachimine Y; Konishi E; Yanagisawa A; Magae J
    World J Surg; 2008 Nov; 32(11):2477-82. PubMed ID: 18758851
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Locoregional recurrence by molecular subtype after multicatheter interstitial accelerated partial breast irradiation: Results from the Pooled Registry Of Multicatheter Interstitial Sites research group.
    Anderson BM; Kamrava M; Wang PC; Chen P; Demanes DJ; Hayes JK; Kuske RR
    Brachytherapy; 2016; 15(6):788-795. PubMed ID: 27743957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.